Effect and Safety of Modified Buzhong Yiqitang on VEGF， IGF-1， TGF-β1， and Immune Function in Postoperative Patients with Non-small Cell Lung Cancer After Chemotherapy / 中国实验方剂学杂志

Objective:To explore the application value of modified Buzhong Yiqitang （BZYQT） in the treatment of postoperative patients with non-small cell lung cancer （Qi deficiency in lung and spleen） after chemotherapy， and to observe its effect on tumor angiogenesis， immune function， tumor indicators， and lung function indicators. Method:Ninety-six patients who were treated in the Kunming municipal hospital of traditional Chinese medicine from March 2018 to February 2020 due to postoperative chemotherapy for non-small cell lung cancer were selected and assigned into a control group （<italic>n</italic>=48， western medicine） and an observation group （<italic>n</italic>=48， western medicine+modified BZYQT） by the random number table. The curative efficacies were compared after the treatment. Result:After treatment， the serum levels of carcinoembryonic antigen （CEA）， cytokeratin 19 fragment 21-1 （CYFRA21-1）， serum insulin-like growth factor-1 （IGF-1）， vascular endothelial growth factor （VEGF）， and transforming growth factor（TGF）-<italic>β</italic>₁ in the observation group were lower than those in the control group （<italic>P</italic><0.05）， while the serum CD4⁺/CD8⁺，CD4⁺ cells， immunoglobulin G （IgG） levels， forced expiratory volume in one second （FEV₁），and FEV₁/forced vital capacity （FVC） in the observation group were higher than those in the control group （<italic>P</italic><0.05）. A significant difference was observed in the total response rate between the observation group ［56.25% （27/48）］ and the control group ［35.42% （17/48）］ （<italic>χ</italic>²＝4.191，<italic>P</italic><0.05）. For adverse reactions，the incidence of bone marrow suppression（<italic>χ</italic>²＝4.002）， gastrointestinal reaction （<italic>χ</italic>²＝7.069），and hepatic and renal injury （<italic>χ</italic>²＝5.151） was lower in the observation group than in the control group （<italic>P</italic><0.05）. Conclusion:For postoperative patients with non-small cell lung cancer （Qi deficiency in lung and spleen） after chemotherapy， western medicine combined with modified BZYQT could ameliorate immune function， promote pulmonary function recovery， improve clinical efficacy， and reduce the incidence of adverse reactions.

Down-regulation of pannexin 2 channel enhances cisplatin-induced apoptosis in testicular cancer I-10 cells / 南方医科大学学报

OBJECTIVE@#To investigate the effect of down-regulation of pannexin 2 (Panx-2) channels on cisplatin-induced apoptosis in I-10 cells.@*METHODS@#The expression of Panx-2 protein in testicular cancer cells was detected with Western blotting. The testicular cancer cell line I-10 was transfected with two short hairpin RNA (shRNA1 and shRNA2) Lipofectamine, the empty vector (NC group) or Lipofectamine2000 (blank control group), and the changes in the expression of Panx-2 was detected with Western blotting. The effects of transfection with a Panx-2 inhibitor on surviving fraction of the cells treated with cisplatin (16 μmol/L) for 24 h, 48 h and 72 h was assessed with MTT assay, and the clonogenic capacity of the cells was evaluated with colony-forming assay. At 8 h after incubation with 16 μmol/L cisplatin, AnnexinV/PI double staining was used to detect the early apoptosis of the cells. After 24 h of treatment with 16 μmol/L cisplatin, the cells were examined for expressions of caspase-3, Bcl-2 and Bax using Western blotting.@*RESULTS@#The expression of Panx-2 was significantly increased in cisplatin-resistant I-10/DDP ( < 0.001) cells and Tcam-2/DDP ( < 0.01) cells as compared with I-10 cells and Tcam-2 cells. Transfection of I-10 cells with shRNA1 and shRNA2 resulted in significantly decreased Panx-2 expression ( < 0.05) and significantly reduced cell surviving fraction ( < 0.001). In the presence of cisplatin, the cells in NC group showed a higher clonogenic efficiency than those in shRNA1 and shRNA2 groups ( < 0.001). The early-stage apoptosis rate of the cells in shRNA1 and shRNA2 groups were significantly higher than that in NC group ( < 0.01). Panx-2 knockdown in I-10 cells significantly increased caspase-3 and Bax expressions ( < 0.05) and significantly decreased the expression of Bcl-2 ( < 0.01).@*CONCLUSIONS@#Down-regulation of Panx-2 channel enhances cisplatin-induced apoptosis in cultured testicular cancer cells.

Inhibitory effect of connexin43 protein on autophagy in cisplatin-resistant testicular cancer I-10 cells / 南方医科大学学报

OBJECTIVE@#To investigate the effect of connexin43 (Cx43) protein on autophagy in cisplatin (DDP)-resistant testicular cancer I-10 cells.@*METHODS@#The expression of Cx43 proteins in testicular cancer I-10 cells and I-10/DDP cells were detected with Western blotting. I-10/DDP cells were transfected with a full- length mouse Cx43 vector (mCx43) Lipofectamine, the empty vector or Lipofectamine (blank control group), and the changes in the expressions of LC3 and p62 proteins were determined with Western blotting. mCherry-GFP-LC3B transfection and transmission electron microscopy were used to analyze the changes in autophagy of the cells with Cx43 overexpression.@*RESULTS@#Cx43 was significantly decreased in I-10/DDP cells compared with I-10 cells ( < 0.01). Transfection of the I-10/DDP cells with mCx43 vector resulted in significantly increased Cx43 expression in the cells ( < 0.01) and caused significantly decreased expression of LC3-Ⅱ ( < 0.01) and increased expression of p62 ( < 0.05) as compared with the negative control cells. Both transmission electron microscopy and mCherry-GFP-LC3B transfection showed that the number of autophagosomes was obviously reduced in mCx43-transfected cells as compared with the negative control cells.@*CONCLUSIONS@#Cx43 inhibits autophagy in cisplatin-resistant testicular cancer I-10 /DDP cells.

Short-term Therapeutic Effect of Recombinant Human Endostatin Combined with Cis-platinum on Malignant Pleural Effusions: A Meta-analysis / 医药导报

Objective To evaluate the efficacy and safety of recombinant human endostatin (rh-endostatin) combined with cis-platinum for patients with malignant pleural effusions.Methods A computer-based online search was performed through Elsevier, PubMed, Medline, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature Database and Wanfang Database.According to the inclusion and exclusion criteria, the randomized controlled trials about short-term therapeutic effect of rh-endostatin combined with cis-platinum on malignant pleural effusions published until December 2015 were selected.Quality of the studies was assessed using modified Jadad scale.After data extraction, a Meta-analysis was performed by RevMan 5.3 software.Relative risk (RR) and its 95% confidence interval (CI) were calculated.The Egger test was performed by Stata 12.0 software.Results Fourteen eligible randomized controlled trials were included in this Meta-analysis involving 1 330 patients,665 in cis-platinum alone group(control group), and 665 in rh-endostatin combined with cis-platinum group(treatment group).The results showed that there were significant improvements in overall response rate (ORR) [73.53% vs 45.41%,RR=1.62,95%CI(1.47,1.78),P<0.000 01] and the rate of quality of life improvement [71.65% vs 46.94%,RR=1.52,95%CI(1.38,1.68),P<0.000 01] in the treatment group, as compared with those of the control group.Meanwhile, there were no statistically significant differences in the rate of cardio toxicity [10.38% vs 5.77%,RR=1.73,95%CI(0.99,3.03),P=0.06].Conclusion This Meta-analysis indicated that in comparison with cis-platinum alone, rh-endostatin combined with cis-platinum has a better therapeutic effect on malignant pleural effusions.

Comparison of Cisplatinum/Paclitaxe concurrent radiotherapy for advanced nasopharyngeal carcinoma / 中国基层医药

Objective To observe the acute side effects and recent therapeutical effect of cisplatinum/paclitaxe concurrent radiotherapy for patients with advanced nasopharyngeal carcinoma.Methods 87 patients with advanced nasopharygeal carcinoma were enrolled.According to the treatment,87 patients were divided into paclitaxe group (groupA,n =43) and cisplatinum group (group B,n =44).The two groups were treated with 6MV-X ray for radiotherapy.The prescription dose of radiation therapy was PGTV,PGTVnd 6 996 cGy/33F,PTV1 6 006 cGy/33F,PTV2 5 096 cGy/28F.The two groups began concurrent chemotherapy in radiotherapy,specific method:group A paclitaxe 30mg/m2,1 time a week,until the end of radiotherapy,group B cisplatinum 80 ～100 mg/m2,every 21 days.Results The recent therapeutical effect of nasopharyngeal lesions and lymph nodes of neck for group A and group B were 88.4％ and 86.4％ (x2 =0.079,P =0.778),88.4％ and 88.6％ (x2 =0.000,P =1.000),respectively.But the occurrence rate of group B ' oral mucosa reaction (x2 =4.295,P =0.038) and gastrointestinal reaction (x2 =4.482,P =0.028) were higher than that of group A.Conclusion Treated with cisplatin in advanced nasopharyngeal carcinoma after radical radiotherapy combined with docetaxel is similar,and the side effect is low,the tolerance of patients is good,curative effect is satisfied.

Clinical study of MRP and LRP mRNA expression in peple with human non-small cell lung cancer after cisplatin chemotherapy / 中国生化药物杂志

Objective To investigate the mRNA expression of the multidrug resistance associated protein and lung resistance protein in human non-small cell lung cancer tissues and their relationship with cis-platinum. Methods 13 samples were collected from patients with non small cell lung cancer before and after chemotherapy, the mRNA expression of MRP and LRP were detected using RT-PCR method, correlation between two genes were studied by Logistic regression analysis. Results Compared with before cisplatin chemotherapy, MRP and LRP expression of patients were increased after chemotherapy(P<0.05).Logistic regression analysis showed that there is no correlation between the two genes(r=0.036,P<0.05). Conclusion Cisplatin chemotherapy can increase the mRNA expression of MRP and LRP, and there is no correlation between the two genes.

Delisheng Injection (), a Chinese medicinal compound, enhanced the effect of cis-platinum on lung carcinoma cell line PGCL3 / 中国结合医学杂志

<p><b>OBJECTIVE</b>To investigate the effect of Delisheng Injection (, DLS), a Chinese medicinal compound, DLS combined with cis-platinum (DDP), an active agent used in lung cancer chemotherapy, on a human highly metastatic giant lung carcinoma cell line PGCL3.</p><p><b>METHODS</b>The suspended PGCL3 cells at 10(5) /mL cultured in 96-well tissue culture plates were divided into 4 groups: DLS treatment group (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL), DDP treatment group (1 μg/mL, 2 μg/mL, 5 μg/mL, 15 μg/mL), combined DLS with DDP treatment group (DLS:DDP 2 μL/mL:1 μg/mL, 5 μL/mL:2 μg/mL, 10 μL/mL:5 μg/mL, 25 μL/mL:15 μg/mL) and a control group. The cytotoxicity of DLS with different concentrations (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL) on PGCL3 cells was determined by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay. Effect of DLS on adhesion of PGCL-3 cells was tested by cell-matrigel adhesion assay. Chemotactic movement model of transwell camerula was used to determine the effect of DLS on invasion and migration of PGCL-3 cells.</p><p><b>RESULTS</b>Compared with the control group, DLS (2 μL/mL, 5 μL/mL, 10 μL/mL, 25 μL/mL) could significantly decrease cell proliferation, adhesion, invasion and migration abilities (P <0.05). Cell adhesion, invasion and migration abilities were significantly decreased after combination treatment of DLS:DDP (2 μL/mL:1 μg/mL, 5 μL/mL:2 μg/mL, 10 μL/mL:5 μg/mL, 25 μL/mL:15 μg/mL) compared with DDP single-agent treatment (1 μg/mL, 2 μg/mL, 5 μg/mL, 15 μg/mL, P<0.05), respectively.</p><p><b>CONCLUSIONS</b>DLS single-agent has a satisfying inhibition effect in PGCL3 cell line and DLS might enhance the inhibition effect of DDP on cancer metastasis. Our research provided a experimental basis about the treatment on highly metastatic lung caner.</p>

The clinical analysis of small cell lung cancer treatment with recombinant human endostatin injection and cis-platinum complexes / 中国基层医药

Objective To explore the clinical effect of small cell lung cancer(SCLC) treatment with recombinant human endostatin injection and cis-platinum complexes.Methods 100 patients with SCLC were divided into 2groups.The experiment group used cis-platinum complexes while the control group used recombinant human endostatin injection.Results The effective rate of experiment group was obviously higher than the control group ( 74.0％ vs60.0％,x2=2.16,P ＜ 0.05 ).The median survival time of experiment group was better than control group( t=2.02,P ＜ 0.05 ).The diverse of untoward effect of two groups had no difference ( P ＞ 0.05).Conclusion Recombinant human endostatin injection and cis-platinum complexes were better therapy for SCLC,which had stable effect,no severe untoward effect and overcome the drug-fast of cis-platinum complexes.

Phase II study of concurrent cisplatinum with ifosfamide and radiotherapy in locally advanced squamous cell cervical carcinoma.

Objective: To evaluate the efficacy and toxicities of cisplatinum and ifosfamide administered concomitantly with radiation therapy in the treatment of locally advanced squamous cell cervical carcinoma (LASCC). Methods: Twenty patients with biopsy-proven squamous cervical carcinoma, FIGO stage II A to III B were entered into this study. All patients received standard radiotherapy (50 Gy in 25 fractions and brachytherapy at a dose of 268-28 Gy). Cisplatinum 70 mg/m2 plus ifosfamide 3 gm/m2 were administered totally for three cycles on Day 1, 21 and 42, concomitant with the radiotherapy schedule. Response and toxicities of treatment were evaluated and long term follow up was performed for disease free survival. Results: All patients received a course of concomitant chemoradiotherapy. Sixteen patients (80%) were able to receive a full course of chemotherapy, the remaining received 1-2 courses because of severe toxicities. The clinical complete response rate was 90% and overall 4 years survival rate was 85%. Grade 3 and 4 leucopenia occurred in 2 cases with one febrile neutropenia. Late complication revealed 2 cases of grade 3 cystitis. Conclusion: This study showed that concomitant chemoradiotherapy with cisplatinum plus ifosfamide was feasible for patients with LASCC. Further study of this regimen should be compared in randomized control trial (RCT) with cisplatinum alone and in the other histologic type of cervical cancer such as adenocarcinoma.

Tumor germinal no seminomatoso del mediastino con invasión pulmonar / Mediastinal non seminomatous germ cell tumor with pulmonary compromise

Los tumores germinales extragonadales representan entre el 1 y 2.5% de los tumores de células germinales (TCG), siendo el mediastino la segunda localización en frecuencia luego de las gónadas. Se presenta el caso de un paciente masculino de 29 años de edad que consulta por tos irritativa de cinco meses de evolución. Se realizaron radiografía, tomografía computada (TC) y resonancia magnética (RM) de tórax y ecografía testicular. Los hallazgos por imágenes, sumados a la presencia de marcadores tumorales elevados (alfa-fetoproteína y gonadotrofina coriónica humana), confirmaron el diagnóstico de TCG extragonadal, avalado posteriormente por la cirugía y la anatomía patológica.

The prevalence of extragonadal germ cell tumors is only 1- 2.5% of all germ cell tumors. The mediastinum is the second most common site affected. We present the case of a 29 years old male pacient, with a persistent cough dating back to five months. We performed chest X-R, thorax CT and MRI and testicular US. The findings of this images besides the presence of elevated levels of alpha-fetoprotein and beta-human gonadotropin confirm the diagnosis of extragonadal germ cell tumor.

Study for the effect of the treatment for the clear-cell cancer of the ovary / 中国癌症杂志

Background and purpose:The clear-cell cancer ovarian cancer have worse prognosis than the other ovarian cancer.The patient's survival rate of the clear-cell ovarian cancer has been analyzed in this article in order to study the effect of the treatment with CAPcytoxan(CTX),cisplatinum(DDP),epiadriamycin(E-ADM)plus mitomycin(MMC).Methods:33 cases(group A)with clear-cell ovarian cancer between Jan.1th 1999 and Dec.31th 1999 were compared to 37 cases(B group)with other pathological ovarian cancer.All cases underwent the tumor reductive surgery and been capable of remain the residual tumor size less than 1 cm.Patients in the two groups all underwent CAP based chemotherapy,and patients in group A with additional MMC chemotherapy at the same time.Group A had been compared with the clear-cell ovarian cancer with the CAP protocol(group C,stage Ⅰ/Ⅱ 15 cases,stage Ⅲ/Ⅳ 9 cases).Results:There was significant statistical different value of the CA125 in stage Ⅰ/Ⅱ before operation and no significant statistical difference for stage Ⅲ/Ⅳ between the two groups.There were significant decrease in the CA125 value for the stage Ⅰ/Ⅱ and no significant decrease for stage Ⅲ/Ⅳ between two groups after three and six courses chemotherapy.There were 11(33.33%)cases developed with endometriosis and 7(21.21%)with deep venous thrombosis(DVT),however the DVT had no direct correlation to the survival rate.The average survival time for stages Ⅰ/Ⅱ in group A and B was(38.3?2.4),and(38.3?2.7)months,compared to(20?3)and(34?4)months in stage Ⅲ/Ⅳ,respectively.There was no significant statistical difference(P=0.471)in four-year survival rate between groups A and B with stage Ⅰ/Ⅱ and there was significant statistical difference(P

Clinical Study on Domestic Amifostine in Prevention of Nephrotoxicity of Cisplatinum / 中国药房

OBJECTIVE:To observe the efficacy and safety of amifostine in prevention of nephrotoxicity induced by cisplatinum(DDP) METHODS:46 patients with malignant tumors were randomly divided into two groups:23 in chemotherapy and amifostine group(trial group)and 23 in single chemotherapy group(control group) Laboratory exmination indices such as blood routine,blood calcium,liver function,blood urea nitrogen,cretinine,and urinary ?1-microglobulin(?1-MG),albumin(Alb) and transferrin(TRF) were monitored at different time period points before and after treatment RESULTS:20 patients in each group completed the whole trial In the two periods of therapy,the peak values of ?1-MG,Alb and TRF of trial group were lower than those of control group(P

Outcome of the ovarian epithelial Cancer stage I-II treated with cyclophosphamide plus cisplatinum or carboplatin.

The retrospective study outcome of the ovarian epithelial cancer stage I-II treated in Obstetrics and Gynaecological Department, Siriraj Hospital during June 1989 – June 1997, received postoperative chemotherapy cyclophosphamide plus cisplatinum (CP) or cyclophosphamide plus carboplatin (C-CP). Stage I disease of unfavourable prognosis 66 cases treated with CP and 25 cases of C-CP, achieved the 5-years disease free survival 82% and 86% respectively (P>0.05). Stage II disease of CP group, 21 cases and C-CP group, 7 cases achieved the 5-years disease-free survival 80% and 82% respectively (P>0.05). The toxicities of chemotreatment were manageble.

The Effect of Irradiation and Cis-diamminedichloroplatinum (II) in the Rat Brain : Analysis of Histopathology at 3 and 6 Months after Treatment / 대한방사선종양학회지

PURPOSE: To evalute the late effect (3 and 6 months) of cis-diamminedichloroplatinum (II) (cisplatin) on the radiation brain damage when the cisplatin was intraperitoneally infused immediately after whole brain irradiation in the rats. MATERIALS AND METHODS: The histolopathological findings of the brain were examined in rat brains at 3 and 6 months after the treatment. The rats were irradiated (20 or 22.5 Gy, RT) or cisplatin was injected intraperitoneally (2, 4, or 8mg/kg, CT) and in combined treatment group, cisplatin (2mg/kg) was injected immediately after irradiation (20 or 22.5 Gy). Histopathological examination was done mostly in irradiation or cisplatin alone groups, because the rats in combined group died during experimental period except 2 rats. RESULTS: The rats treated with cisplatin showed marked epithelial vacuolation with perivascular edema and vascular dilatation in choroid plexus at 3 months as well as multifocal necrosis involving fimbria and cerebellar hemispheres at 3 and 6 months. The changes were more prominent in rats with 2mg/kg injection compared to rats with 8mg/kg injection.The rats with RT and combined CT and RT showed characteristic delayed irradiation effects such as focal coagulation necrosis and vascular changes, which were more marked than previous reports. Prominent perivascular and leptomeningeal astrocytic proliferation was well documented by anti-GFAP antibody. Cisplatin treatment did not enhance the effect of radiation-induced changes of blood vessels and astrocytic proliferation. CONCLUSION: The focal necrosis was the most consistently noted finding in this study, it suggested the possibility to use this as an evaluation factor for combined effects of RT and cisplatin.

The Effect of Irradiation and Cis-diamminedichloroplatinum (II) in the Rat Brain : Analysis of Histopathology at 3 and 6 Months after Treatment / 대한방사선종양학회지

PURPOSE: To evalute the late effect (3 and 6 months) of cis-diamminedichloroplatinum (II) (cisplatin) on the radiation brain damage when the cisplatin was intraperitoneally infused immediately after whole brain irradiation in the rats. MATERIALS AND METHODS: The histolopathological findings of the brain were examined in rat brains at 3 and 6 months after the treatment. The rats were irradiated (20 or 22.5 Gy, RT) or cisplatin was injected intraperitoneally (2, 4, or 8mg/kg, CT) and in combined treatment group, cisplatin (2mg/kg) was injected immediately after irradiation (20 or 22.5 Gy). Histopathological examination was done mostly in irradiation or cisplatin alone groups, because the rats in combined group died during experimental period except 2 rats. RESULTS: The rats treated with cisplatin showed marked epithelial vacuolation with perivascular edema and vascular dilatation in choroid plexus at 3 months as well as multifocal necrosis involving fimbria and cerebellar hemispheres at 3 and 6 months. The changes were more prominent in rats with 2mg/kg injection compared to rats with 8mg/kg injection.The rats with RT and combined CT and RT showed characteristic delayed irradiation effects such as focal coagulation necrosis and vascular changes, which were more marked than previous reports. Prominent perivascular and leptomeningeal astrocytic proliferation was well documented by anti-GFAP antibody. Cisplatin treatment did not enhance the effect of radiation-induced changes of blood vessels and astrocytic proliferation. CONCLUSION: The focal necrosis was the most consistently noted finding in this study, it suggested the possibility to use this as an evaluation factor for combined effects of RT and cisplatin.

Change of Chemosensitivity and Cellular Characteristics of Cisplatinum Resistant Human Bladder Cancer Cells Induced by Long-term Cisplatinum Treatment / 대한비뇨기과학회지

PURPOSE: Cisplatinum has the therapeutic efficacy against a bladder cancer. However, the response is often limited due to appearance of drug-resistant tumor cells. The studies of establishment and characterization of cisplatinum-resistant tumor cells are considered to be helpful in elucidating the underlying mechanism of acquired resistance to cisplatinum in human tumors. MATERIALS AND METHODS: We established cisplatinum-resistant cell lines sequentially, T24Rl and T24R2, which show resistance to cisplatinum at a concentration of 1 and 2microgram /ml, respectively, by the stepwise exposure of T24 human bladder cancer cell to increasing concentrations of cisplatinum. RESULTS: The resistance to cisplatinum of T24Rl and T24R2 cells was 13- and 18-fold that of the parental T24 cells, respective1y. Growth, DNA synthesis and cell cycle distribution of T24Rl and T24R2 cells were not different from those of the parental T24 cells. CONCLUSIONS: These cisplatinum-resistant bladder tumor cell lines could be a useful model to elucidate the biochemical and molecular mechanism Involved In the cisplatinum resistance.

Therapeutic Results of Concurrent Chemoradiation in Locally Advanced Uterine Cervical Cancer / 대한치료방사선과학회지

PURPOSE: Despite a development fo therapeutic machines and advance in modern radiation therapy techniques, locally advanced cervical carcinoma has shown high rate of local failure and poor survival rate. Combination of chemotherapy and radiotherapy demonstrated benefit in improving local control and possibly the overall survival. Our study was performed to evaluate effect of concurrent chemoradiation on locally advanced uterine cervical cancer. METHODS AND MATERIALS: Twenty six patients with locally advanced stage(FIGO stage IIB with > or = 5 cm in diameter, III, IVA) were treated with combination of radiation therapy and concurrent cisplatinum between May of 1988 and Septermber of 1993 at our hopital. Radiation therapy consisted of external irradiation and 1-2 sessions of intracavitary irradiation, Cisplatinum was administered in bolus injection of 25mg/m(2) at weekly intervals during the course of external radiation therapy. RESULTS: Of the 26 patients, twenty-five patients were evaluable for estimation of response. Median follow-up period was 25 months with ranges from 3 to 73 months. Stage IIB, III, and IVA were 16, 5,4 patients, respectively. Twenty patients were squamous cell carcinoma. Response was noted in all 25 patients: complete response(CR) in 17/25(68%), partial response(PR) in 8/25(32%). Of the 24 patients except one who died of sepsis at 3 months follow-up, seventeen patients(70.8%) maintained local control in the pelvis: 16/17(94.1%) in CR, 1/17(14.3%) in PR. Fourteen of the 17 patients with CR are alive disease free on the completion of follow-up. Median survival is 28 months for CR and 15 months for PR. Analysis of 5-year survival by stage shows 11/16(59.8) in IIB, 3/5(60.6%) in III, and 1/4(25.0%) in IVA. Overall 5-year survival rate was 55.2%. Ten Patients recurred: 4 at locoegional,3 in distant metastasis and 3 with locoregional and distant site. Toxicity by addition of cisplatinum was not excessive. CONCLUSION: Although the result of this study was obtained from small number of patients, it is rather encouraging in view of markedly improved response rate compared with the results of historical group.

Additional megestrol acetate with cis-platinum combination regimens in treatment of advanced ovaian epithelial cancer.

Patients with advanced ovarian epithelial cancer were randomized for additional oral megestrol acetate 160 mg/day for 3 weeks and repeated simultaneously every cycle of the three cis-platinum combination regimens. Fifteen patients of AP and 18 cases of AP plus megestrol acetate showed a higher incidence of weight gain 26.66% versus 94.44% (P<0.05), lower incidence of nausea-vomiting 73.33% versus 22.22% (P<0.05), increase of appetite and sense of well being 26.66% versus 77.77% (P<0.05), and incidence of good performance 53.33% versus 66.66% (P>0.05). Fifteen cases of EP and 17 cases of EP plus megestrol acetate achieved a higher incidence of weight gain 20.00% versus 88.23% (P<0.05), incidence of nausea-vomiting 73.33% versus 41.17% (P>0.05), better incidence of good appetite and sense of well being 20.00% versus 70.58% (P<0.05), and incidence of good performance 26.66% versus 64.70% (P>0.05). Nineteen cases of CAP and 15 cases of CAP plus megestrol acetate achieved a higher incidence of weight gain 31.57% versus 86.66% (P<0.05), lower incidence of nausea-vomiting 89.47% versus 40.00% (P>0.05), incidence of good appetite and sense of well being 47.36% versus 80.00% (P>0.05), and incidence of good performance 57.89% versus 66.66% (P>0.05). The response rate of disease to the additional megestrol acetate of the three regimens showed no significant change.

Cyclophosphamide, adriamycin and cis-platinum in treatment of ovarian common epithelial cancer stage III-IV.

Twelve patients with ovarian common epithelial cancer stage III, IV were treated by post operative chemotherapy; combination of cyclophosphamide, adriamycin and cis-diamminedichloroplatinum. Their revealed overall response rate was 83.3%, clinical complete remission was 66.6%, with a follow-up period of 10.0-23.5 months, and was negative on second look operation 83.3%. The response rate was 77.7%, for residual cancer > 5.0 cm. with a clinical complete remission 55.5%, and was negative on second look operation 66.6%.